Augmentation Therapy for Alpha-1 Antitrypsin Deficiency: Patient Experiences With Self-Infusion, Home Providers, and Clinics.
AATD
COPD
alpha-1 antitrypsin deficiency
antitrypsin
self-infusion
Journal
Chronic obstructive pulmonary diseases (Miami, Fla.)
ISSN: 2372-952X
Titre abrégé: Chronic Obstr Pulm Dis
Pays: United States
ID NLM: 101635411
Informations de publication
Date de publication:
26 Oct 2023
26 Oct 2023
Historique:
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Currently approved therapies for individuals with alpha-1 antitrypsin deficiency (AATD) are intravenously infused products. The burdens and demographics of infusion practices in the United States are not well-characterized. What is the prevalence of different infusion practices in the United States? AlphaNet disease management participants completed a survey that captured current and past infusion practices. Data regarding the reasons for choosing their current infusion practice, problems with past infusion practices, resources required, and support services utilized were collected from February 8, 2022 through July 1, 2022. Among 5266 individuals, infusions happened at home by health care providers (60.2%), at infusion clinics (30.6%), and by self-infusion (8.1%). Self-infusion prevalence increased with time on therapy and was more prevalent in younger individuals (61.2 ± 10.5 years) compared to users of other infusion practices (64.1 ± 11.0 years), ( Self-infusion of alpha-1 antitrypsin is feasible and associated with high satisfaction scores. Recommendations for catheter care, infusion support, and cost management are informed by survey results.
Sections du résumé
Background
UNASSIGNED
Currently approved therapies for individuals with alpha-1 antitrypsin deficiency (AATD) are intravenously infused products. The burdens and demographics of infusion practices in the United States are not well-characterized.
Research Question
UNASSIGNED
What is the prevalence of different infusion practices in the United States?
Study Design and Methods
UNASSIGNED
AlphaNet disease management participants completed a survey that captured current and past infusion practices. Data regarding the reasons for choosing their current infusion practice, problems with past infusion practices, resources required, and support services utilized were collected from February 8, 2022 through July 1, 2022.
Results
UNASSIGNED
Among 5266 individuals, infusions happened at home by health care providers (60.2%), at infusion clinics (30.6%), and by self-infusion (8.1%). Self-infusion prevalence increased with time on therapy and was more prevalent in younger individuals (61.2 ± 10.5 years) compared to users of other infusion practices (64.1 ± 11.0 years), (
Interpretation
UNASSIGNED
Self-infusion of alpha-1 antitrypsin is feasible and associated with high satisfaction scores. Recommendations for catheter care, infusion support, and cost management are informed by survey results.
Identifiants
pubmed: 37549313
doi: 10.15326/jcopdf.2023.0430
pmc: PMC10699483
doi:
Types de publication
Journal Article
Langues
eng
Pagination
392-399Informations de copyright
JCOPDF © 2023.
Références
Int Arch Allergy Immunol. 2013;161 Suppl 1:17-20
pubmed: 23689240
Int J Chron Obstruct Pulmon Dis. 2022 Jan 05;17:53-64
pubmed: 35023913
Int J Chron Obstruct Pulmon Dis. 2021 Nov 01;16:2983-2996
pubmed: 34754184
Am J Prev Med. 2011 Dec;41(6 Suppl 4):S338-45
pubmed: 22099356
Int Arch Allergy Immunol. 2013;161 Suppl 1:26-7
pubmed: 23689242
Haemophilia. 2012 Jul;18(4):516-20
pubmed: 22292416
Respir Care. 2018 Jun;63(6):690-698
pubmed: 29794204
COPD. 2009 Feb;6(1):31-40
pubmed: 19229706
Int Arch Allergy Immunol. 2013;161 Suppl 1:10-6
pubmed: 23689239
Clin Chest Med. 2020 Sep;41(3):339-345
pubmed: 32800189
Haemophilia. 2004 Mar;10(2):118-33
pubmed: 14962201
World Allergy Organ J. 2012 Dec;5(12):182-99
pubmed: 23282420
Clin Lab Haematol. 1979;1(1):13-27
pubmed: 535301
ERJ Open Res. 2019 Mar 11;5(1):
pubmed: 30863774
Front Pharmacol. 2021 Apr 15;12:575402
pubmed: 33935692
J Allergy Clin Immunol. 2006 Apr;117(4):904-8
pubmed: 16630950
Pulm Ther. 2022 Mar;8(1):95-103
pubmed: 35067906
Eur J Dermatol. 2009 Mar-Apr;19(2):147-51
pubmed: 19264579
Int Arch Allergy Immunol. 2013;161 Suppl 1:21-5
pubmed: 23689241
Clin Exp Immunol. 2007 Jan;147(1):11-7
pubmed: 17177958
Haemophilia. 2008 Jan;14(1):65-7
pubmed: 18070063